Winship Trial Reduces Mortality Rate for APL Patients

Winship's APL team (left to right): Martha Arellano, Kaitlin Sitchenko, Anand P. Jillella, Vamsi Kota, Ann Shen, Emily Bennett.

Winship’s APL team (left to right): Martha Arellano, Kaitlin Sitchenko, Anand P. Jillella, Vamsi Kota, Ann Shen, Emily Bennett.

Winship oncologist Anand Jillella, MD is spearheading a clinical trial for patients with Acute Promyelocytic Leukemia (APL) that could change the mortality rate for this disease on a major scale.

Often called the heart attack of leukemias, APL is a highly aggressive disease that is curable if treated early. A third of patients, however, do not survive the first month of treatment. By observing and analyzing the problem, Jillella and his team of physicians, nurses, and research staff came up with a collaborative approach that decreases mortality from 30 percent to about five percent. This new trial is open to patients all across the country.

Jillella has found that some physicians who treat patients with APL may not be familiar with the potential complications that can develop during treatment. He took a very detailed treatment algorithm and boiled it down to a three-step process that can be easily shared. “As soon as we get a call from a community physician, we send the simplified algorithm via smart phone,” says Jillella. “We come up with a treatment plan based on what the patient is experiencing and follow up with them regularly to get them through that difficult first month.”

RELATED RESOURCES:
Getting the Best Cancer Treatments into Outlying Communities
Clinical Trials: Leading the Way to Better Health Care

Tags: , , , , ,